Mereo BioPharma Group plc Correction to Issued Share Capital (4849Z)
August 31 2018 - 1:25PM
UK Regulatory
TIDMMPH
RNS Number : 4849Z
Mereo BioPharma Group plc
31 August 2018
Mereo BioPharma Group plc
("Mereo" or the "Company")
Correction to Issued Share Capital
London, 31 August 2018 - Mereo BioPharma Group plc (AIM: MPH), a
clinical stage, UK-based, biopharmaceutical company focused on rare
diseases, announces a correction to the previously announced number
of the Company's ordinary shares of GBP0.003 each ("Ordinary
Shares") in issue.
On 23 July 2018 the Company announced that it had issued,
conditional on admission, 95,222 Ordinary Shares, pursuant to an
exercise of employee share options. These shares were admitted to
trading on AIM on 24 July 2018. The Company has become aware that
an administrative error has occurred and only 10,000 of the 95,222
Ordinary Shares were issued. Accordingly, the Company has arranged
with the London Stock Exchange to cancel the additional 85,222
Ordinary Shares.
The Company confirms that it now has a total of 71,155,050
Ordinary Shares in issue. This figure may be used by shareholders
as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change to their interest in the Company.
Enquiries:
Mereo BioPharma Group plc +44 (0)333 023 7300
Denise Scots-Knight, Chief Executive
Officer
Richard Jones, Chief Financial Officer
Cantor Fitzgerald Europe (Nominated
Adviser and Broker) +44 (0)20 7894 7000
Phil Davies
Will Goode
Rick Thompson
RBC Capital Markets (Joint Broker) +44 (0)20 7653 4000
Rupert Walford
Jamil Miah
FTI Consulting (Public Relations Adviser) +44 (0)20 3727 1000
Simon Conway
Brett Pollard
Burns McClellan (US Public Relations
Advisor to Mereo Biopharma) +01 (0) 212 213 0006
Lisa Burns
Steven Klass
About Mereo
Mereo is a biopharmaceutical company focused on the development
and commercialization of innovative therapeutics that aim to
improve outcomes for patients with rare diseases. The portfolio
currently consists of four clinical-stage product candidates, each
of which were acquired from large pharmaceutical companies: BPS-804
(setrusumab) for the treatment of osteogenesis imperfecta ("OI");
MPH-966 (alvelestat) for the treatment of severe alpha-1
antitrypsin deficiency ("AATD"); BCT-197 for the treatment of acute
exacerbations of chronic obstructive pulmonary disease, ("AECOPD");
and BGS-649 for the treatment of hypogonadotropic hypogonadism
("HH") in obese men. Each of the Company's product candidates has
generated positive clinical data for Mereo's target indication or
in a related indication. The Company's strategy is to selectively
acquire product candidates that have already received significant
investment from pharmaceutical companies and that have substantial
preclinical, clinical and manufacturing data packages. Since
inception the Company has commenced large, randomized,
placebo-controlled Phase 2 clinical trials for three of the product
candidates and has previously announced positive top-line results
from two of its clinical trials: a Phase 2 trial with BCT-197 in
December 2017 and a Phase 2b dose-ranging study with BGS-649 in
March 2018.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCSDIFWFFASEFA
(END) Dow Jones Newswires
August 31, 2018 13:25 ET (17:25 GMT)
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From Apr 2024 to May 2024
Mereo Biopharma (LSE:MPH)
Historical Stock Chart
From May 2023 to May 2024